Northwest Biotherapeutics
Profile Unclaimed

Northwest Biotherapeutics Reviews

0 Reviews
0 Reviews

Recommend to a friend
Approve of CEO
(no image)
Alton L. Boynton
0 Ratings

Northwest Biotherapeutics Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters Bethesda, MD
Size 6 to 15 Employees
Founded Unknown
Type Company - Public (NWBO)
Industry Biotech & Pharmaceuticals
Revenue Less than $1 million (USD) per year

Northwest Biotherapeutics wants to bring out the killer in you. The development-stage firm's DCVax vaccine platform uses dendritic cells (a type of white blood cells) obtained from a patient's blood to program that patient's own T cells to kill cancer cells. Northwest Biotherapeutics' two DCVax product candidates are being targeted to treat brain and prostate cancer. Both candidates are in late-stage clinical trials. If successful, the therapies could work in conjunction with more traditional cancer treatments. Toucan Capital holds over 85% of the company's shares... More

Work at Northwest Biotherapeutics? Share Your Experiences

Northwest Biotherapeutics

Click to Rate